ARCTICZYMES Aktie

 

(Tromsø, 04 June 2025) ArcticZymes Technologies ASA (OSE:AZT) will present at Handelsbanken's Small & Mid Cap Seminar 2025 in Stockholm taking place today, 04 June 2025. Estimated start of the presentation will be at 11.20 CET Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com...

Marit Sjo Lorentzen, VP Operations has on 3 June purchased 3.400 shares in ArcticZymes Technoloiges ASA for NOK 16.00 per share. Following this transaction holds Mrs. Lorentzen 28.731 shares and 135,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contact Børge Sørvoll CFO +4795290187 ir@arcticzymes.com...

Tromsø, Norway, May 28th, 2025 – ArcticZymes Technologies ASA (OSE: AZT), in collaboration with the Austrian Centre of Industrial Biotechnology (acib), has extended their joint research partnership for another three years, focusing on delivering significantly enhanced purification methods for bionanoparticles (BNPs), critical for safer, more effective gene therapies, vaccines, and cancer treatments. The ongoing phase of the project, which began in April 2024, demonstrated that focusing on the removal of chromatin rather than accessible forms of DNA, is essential for improved purification of...

(Tromsø 27. May 2025) The Annual General Meeting of ArcticZymes Technologies ASA (OSE:AZT) was held today, 27. May 2025 as a physical meeting with opportunity for virtual participation. Attached to this announcement are the minutes of the Annual General Meeting in Norwegian and an English translation. All items on the agenda were adopted as proposed. For further information, please contact: Børge Sørvoll CFO +47 952 90187 borge.sorvoll@arcticzymes.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act....

Tromsø, Norway, 18 December 2024 - The Board of Directors in ArcticZymes Technologies ASA (the "Company") has decided to grant 335,000 share options to senior management under the Company's long-term incentive plan. The strike price of the options are NOK 15.00 per share.The options will have 12 months waiting period, 36 months vesting period and 12 months exercise period. The options are granted in accordance with the Company's guidelines for remuneration to senior management approved by the Annual General Meeting on 20 May 2021. The following primary insiders have been granted options:...

Tromsø, Norway, December 9, 2024 – ArcticZymes Technologies (OSE:AZT) introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector. The new SAN HQ ELISA SensoPlus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as...

Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A. The study demonstrates how integrating M-SAN HQ nuclease with heparin affinity chromatography streamlines MV purification, achieving unmatched levels of both purity and yield. Innovative Approach to MV Purification The study, titled "Highly Pure Measles Virus Generated by Combination of Salt-Active Nuclease...

(Tromsø 11 November 2024) Olav Lanes,  VP R&D and applications has on 11 November purchased 5.000 shares in ArcticZymes Technologies ASA for NOK 13,90 per share. Following this transaction holds Mr. Lanes 7.000 shares and 100.000 options in the company. Marit Sjo Lorentzen, VP Operations has on 11 November purchased 5.000 shares in ArcticZymes Technoloiges ASA for NOK 13.88 per share. Following this transaction holds Mrs. Lorentzen 25.331 shares and 100,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the...

(Tromsø 08 November 2024) Frank Mathias, Chairman of the Board has on 07 November purchased 2.000 shares in ArcticZymes Technologies ASA for EUR 1.194 per share. Following this transaction holds Mr. Mathias 9.000 shares in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contact Børge Sørvoll CFO +4795290187 ir@arcticzymes.com About ArcticZymes Technologies ASA ArcticZymes Technologies is...

(Tromsø 07 November 2024) Michael Akoh, CEO has on 07 November purchased 7.660 shares in ArcticZymes Technologies ASA for NOK 13.26 per share. Following this transaction holds Mr. Akoh 7.660 shares and 200.000 options in the company. Sharon Brownlow,  Board member has on 7 November purchased 10.570 shares in ArcticZymes Technoloiges ASA for GBP 0.9378 per share. Following this transaction holds Mrs. Brownlow 10.570 shares in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12...

Tromsø, Norway, November 6th, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 24.1 million and an EBITDA of NOK -2.3 million for the third quarter of 2024. Financial Highlights: · Revenue for Q3 2024 was NOK 24.1 million, compared to NOK 31.2 million in Q3 2023. Year-to-date revenue totals NOK 81.7 million (9M 2023: NOK 90.6 million). · Revenue for the quarter was in particular impacted by lower sales to two key accounts. · Biomanufacturing revenue has grown for the third consecutive quarter, demonstrating resilience in a challenging macroeconomic environment....

Rome, Italy – October 24, 2024 – ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference. The annual ESGCT conference is renowned for spotlighting breakthrough innovations in gene and cell therapy. It acts as a global stage for companies to showcase the latest scientific and technological achievements impacting their work in the biotherapeutics industry.   In this context, ArcticZymes salt active nucleases...

(Tromsø, 19 September 2024) ArcticZymes Technologies ASA (OSE:AZT) will present at Pareto Securities 15th Healthcare Conference in Stockholm taking place today, 19 September 2024. Estimated start of the presentation will be at 13.10 CET. Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com...

September 17th, 2024, Tromsø, Norway — ArcticZymes Technologies (OSE: AZT) has released a timely whitepaper in Select Science titled "Efficient Chromatin Removal in Viral Vector Manufacturing Using Salt-Active Nucleases." As global attention on salt-active nucleases increases, this whitepaper reinforces ArcticZymes' leadership by offering crucial insights that help viral vector manufacturers optimize their downstream processing (DSP) and make informed decisions. The peer-reviewed studies cited in this paper will help leverage rising interest about Salt Active Nucleases and guide the...

ArcticZymes Technologies presents on August 22, 08:30 CET its interim report for the second quarter and first 6 months 2024 Speaker at the presentation will be , CEO, MIchael Akoh, CFO and Børge Sørvoll Please find the presentation attached. For more information, please contact Børge Sørvoll CFO +47 952 90 187 borge.sorvoll@arcticzymes.com...

(Tromsø 26. June 2024) The Annual General Meeting of ArcticZymes Technologies ASA (OSE:AZT) was held today, 26. June 2024 as a virtual meeting with electronic participation. Attached to this announcement are the minutes of the Annual General Meeting in Norwegian and an English translation. All items on the agenda, except for point 9; board authorization to increase the share capital, were adopted. For further information, please contact: Børge Sørvoll CFO +47 952 90187 borge.sorvoll@arcticzymes.com This information is subject to the disclosure requirements pursuant to section 5 -...

Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomination of Dr. Frank Mathias as the new Chairman of the Board. Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global...

Tromsø, Norway, June 17, 2024 - ArcticZymes Technologies ASA (OSE: AZT) has today executed a contract with The Research Council of Norway, securing up to 11.8 MNOK for a collaborative project aimed at supporting the advanced therapy biomanufacturing sector. This follows a previously announced research grant awarded by the Norwegian Research Council. The agreements with the Norwegian Research Council and the project partners, the University of Tromsø - The Arctic University of Norway, and SINTEF Industri have now been finalized, marking the project's commencement. The project has been named...